Ralf Fliegert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ralf Fliegert has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Stefanie Etzold
Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
5 shared publications- Susanne Pfefferle
Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
5 shared publications Chris Meier
Organic Chemistry, Department of Chemistry, University of Hamburg, Hamburg, Germany
4 shared publicationsHenning Tidow
The Hamburg Advanced Research Center for Bioorganic Chemistry (HARBOR) & Department of Chemistry, Institute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany
4 shared publications- Julia Berger
Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
4 shared publications - Maria Garcia Alai
European Molecular Biology Laboratory, Hamburg Outstation, Hamburg, Germany
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
Generation of a fully infectious SARS-CoV-2 encoding an internally tagged nsp3
The analysis of coronavirus replicase proteins during authentic infection is experimentally challenging, particularly for large and essential components embedded within virus-induced replication organelles. Non-structural protein 3 (nsp3), the largest coronavirus replicase protein, plays a central role in replication organelle formation, but has remained difficult to genetically manipulate. Here, we generated a fully infectious recombinant SARS-CoV-2 encoding an internal ALFA epitope tag upstream of the Mac1 domain within nsp3 (rALFA). Growth kinetics analyses demonstrated that rALFA replicated with kinetics and peak titers comparable to those of untagged recombinant SARS-CoV-2, and retained lytic infection. Tagged nsp3 displayed subcellular localization patterns equal to those observed in infections with untagged virus, and nanobody-based detection enabled robust visualization of nsp3 in infected cells. This internally tagged SARS-CoV-2 establishes a useful experimental platform for future analyses of nsp3 localization and replication organelle dynamics under authentic infection conditions, and provides a foundation for subsequent functional studies. IMPORTANCE: The manuscript presents a practical tool that advances coronavirus methodology.
- 2 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
Open AccessGeneration of a fully infectious SARS-CoV-2 encoding an internally tagged nsp3
The analysis of coronavirus replicase proteins during authentic infection is experimentally challenging, particularly for large and essential components embedded within virus-induced replication organelles. Non-structural protein 3 (nsp3), the largest coronavirus replicase protein, plays a central role in replication organelle formation, but has remained difficult to genetically manipulate. Here, we generated a fully infectious recombinant SARS-CoV-2 encoding an internal ALFA epitope tag upstream of the Mac1 domain within nsp3 (rALFA). Growth kinetics analyses demonstrated that rALFA replicated with kinetics and peak titers comparable to those of untagged recombinant SARS-CoV-2, and retained lytic infection. Tagged nsp3 displayed subcellular localization patterns equal to those observed in infections with untagged virus, and nanobody-based detection enabled robust visualization of nsp3 in infected cells. This internally tagged SARS-CoV-2 establishes a useful experimental platform for future analyses of nsp3 localization and replication organelle dynamics under authentic infection conditions, and provides a foundation for subsequent functional studies. IMPORTANCE: The manuscript presents a practical tool that advances coronavirus methodology.
- Open Access
- 25 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10227
Publisher Correction: Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2
- 25 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10227
Open AccessPublisher Correction: Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2
- Open Access
- 15 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9831
Publisher Correction: Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2
- 15 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9831
Open AccessPublisher Correction: Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2
- Open Access
- 27 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7416
Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2
Enzymatically active macrodomains of (+)ss-RNA viruses mediate immune evasion by countering ADP-ribosylation and are therefore promising druggable targets. Here we report testing of ADP / ADP-ribose analogues for their ability to inhibit Mac1 of SARS-CoV-2, measurement of the affinity of active compounds and characterization of their binding mode by cocrystallization, uncovering critical molecular determinants of protein-ligand interaction. Key findings of the resulting structure-activity relationship (SAR) include that inhibitory potency is improved by either replacing the distal ribose of ADP-ribose by a small alkyl group or the adenine N7 by carbon. Based on insights from the SAR, we show β-methyl-GS-441524-diphosphate as nanomolar inhibitor that exhibits >1000-fold selectivity over human MacroD1 and MacroD2. Addition of C 11 -acyloxybenzyl (AB)-masking groups yields a membrane permeable, lipophilic prodrug that inhibits SARS-CoV-2 in cell culture (EC 50 0.06 µM) while exhibiting low cytotoxicity (CC 50 > 50 µM). Replacement of the terminal methyl phosphate with an ethyl phosphonate increases stability of the prodrug with little effect on toxicity and antiviral potency (EC 50 = 0.03 µM), making it a membrane-permeable nucleotide-based prodrug against viral macrodomains.
- 27 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7416
Open AccessDesign, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2
Enzymatically active macrodomains of (+)ss-RNA viruses mediate immune evasion by countering ADP-ribosylation and are therefore promising druggable targets. Here we report testing of ADP / ADP-ribose analogues for their ability to inhibit Mac1 of SARS-CoV-2, measurement of the affinity of active compounds and characterization of their binding mode by cocrystallization, uncovering critical molecular determinants of protein-ligand interaction. Key findings of the resulting structure-activity relationship (SAR) include that inhibitory potency is improved by either replacing the distal ribose of ADP-ribose by a small alkyl group or the adenine N7 by carbon. Based on insights from the SAR, we show β-methyl-GS-441524-diphosphate as nanomolar inhibitor that exhibits >1000-fold selectivity over human MacroD1 and MacroD2. Addition of C 11 -acyloxybenzyl (AB)-masking groups yields a membrane permeable, lipophilic prodrug that inhibits SARS-CoV-2 in cell culture (EC 50 0.06 µM) while exhibiting low cytotoxicity (CC 50 > 50 µM). Replacement of the terminal methyl phosphate with an ethyl phosphonate increases stability of the prodrug with little effect on toxicity and antiviral potency (EC 50 = 0.03 µM), making it a membrane-permeable nucleotide-based prodrug against viral macrodomains.
- Open Access
Domain-Specific Agonist Binding Affinities Explain Structural and Functional Regulation of TRPM2
TRPM2 is a Ca²⁺-permeable cation channel activated by ADP-ribose (ADPR) and oxidative stress, yet the relative contributions of its two nucleotide-binding domains, MHR1/2 and NUDT9H, remain incompletely understood. Here, we quantitatively determine the affinities of the isolated human TRPM2 MHR1/2 and NUDT9H domains for ADPR, 2’-deoxy-dADPR (dADPR), and 8-Br-cADPR using biophysical approaches. The MHR1/2 domain binds ADPR with high affinity (K d ≈ 0.5 µM), whereas the NUDT9H domain displays substantially lower affinity (K d ≈ 192 µM), revealing a difference of nearly three orders of magnitude. Mutational analysis demonstrates that alterations in MHR1/2 strongly affect ligand binding and channel activation, while mutations within NUDT9H that markedly reduce ligand affinity exert only modest effects on gating. In parallel, we quantify intracellular ADPR concentrations in resting and hydrogen peroxide–stimulated cells and find that they remain well below the affinity required for substantial NUDT9H occupancy. Together, our findings indicate that high-affinity binding to the MHR1/2 domain is sufficient to drive TRPM2 activation under physiological conditions, whereas the NUDT9H domain likely contributes to maintaining the structural integrity of the channel rather than directly mediating ligand-dependent activation. These results provide a quantitative framework for understanding ligand-dependent TRPM2 regulation in cells.
Open AccessDomain-Specific Agonist Binding Affinities Explain Structural and Functional Regulation of TRPM2
TRPM2 is a Ca²⁺-permeable cation channel activated by ADP-ribose (ADPR) and oxidative stress, yet the relative contributions of its two nucleotide-binding domains, MHR1/2 and NUDT9H, remain incompletely understood. Here, we quantitatively determine the affinities of the isolated human TRPM2 MHR1/2 and NUDT9H domains for ADPR, 2’-deoxy-dADPR (dADPR), and 8-Br-cADPR using biophysical approaches. The MHR1/2 domain binds ADPR with high affinity (K d ≈ 0.5 µM), whereas the NUDT9H domain displays substantially lower affinity (K d ≈ 192 µM), revealing a difference of nearly three orders of magnitude. Mutational analysis demonstrates that alterations in MHR1/2 strongly affect ligand binding and channel activation, while mutations within NUDT9H that markedly reduce ligand affinity exert only modest effects on gating. In parallel, we quantify intracellular ADPR concentrations in resting and hydrogen peroxide–stimulated cells and find that they remain well below the affinity required for substantial NUDT9H occupancy. Together, our findings indicate that high-affinity binding to the MHR1/2 domain is sufficient to drive TRPM2 activation under physiological conditions, whereas the NUDT9H domain likely contributes to maintaining the structural integrity of the channel rather than directly mediating ligand-dependent activation. These results provide a quantitative framework for understanding ligand-dependent TRPM2 regulation in cells.
- Open Access
- 2 October 2025
- Published by MDPI AG in Preprints.org
Generation and Characterization of a Tagged Recombinant SARS‐CoV‐2 for Functional Replicase Studies
Coronavirus macrodomains have been described as important virulence factors which compromise type-I interferon (IFN) signaling, but their precise mechanism of action remains unclear and robust tools for interactome studies are still missing. Using reverse genetics, we generated and characterized recombinant SARS-CoV-2 (rALFA) encoding an ALFA-tag upstream of Mac1 to enable targeted analysis during viral replication. Infection assays and immunofluorescence staining (IF) were performed in comparison to recombinant SARS-CoV-2 without replicase modifications (rWT) and a variant lacking Mac1 (rΔMac1). All recombinant variants proved replication competent. Preserved lytic infection was confirmed for rALFA with identical plaque morphology compared to rWT and rΔMac1. On Vero E6 cells the recombinant viruses reached comparably high titres (mean PFU/ml rWT: 3.11 x106, rΔMac1: 1.20 x107, rALFA: 7.55 x106), on Calu-3 cells titres reached at 72 hpi (mean PFU/ml rWT: 8.89 x107, rΔMac1: 9.33 x105, rALFA: 2.28 x107) were comparable for rWT and rALFA yet significantly lower for rΔMac1. Immunofluorescence staining confirmed robust expression and cytoplasmic localization of the tagged nsp3. ALFA-tagging allowed for specific, super resolved IF images of Mac1 by anti-ALFA nanobodies in rALFA infected A549 cells. In conclusion, the tagged SARS-CoV-2 represents a versatile tool for functional studies of nsp3 interactions and dynamics of subcellular trafficking during infection, prospectively enabling validation of new therapeutic approaches.
- 2 October 2025
- Published by MDPI AG in Preprints.org
Open AccessGeneration and Characterization of a Tagged Recombinant SARS‐CoV‐2 for Functional Replicase Studies
Coronavirus macrodomains have been described as important virulence factors which compromise type-I interferon (IFN) signaling, but their precise mechanism of action remains unclear and robust tools for interactome studies are still missing. Using reverse genetics, we generated and characterized recombinant SARS-CoV-2 (rALFA) encoding an ALFA-tag upstream of Mac1 to enable targeted analysis during viral replication. Infection assays and immunofluorescence staining (IF) were performed in comparison to recombinant SARS-CoV-2 without replicase modifications (rWT) and a variant lacking Mac1 (rΔMac1). All recombinant variants proved replication competent. Preserved lytic infection was confirmed for rALFA with identical plaque morphology compared to rWT and rΔMac1. On Vero E6 cells the recombinant viruses reached comparably high titres (mean PFU/ml rWT: 3.11 x106, rΔMac1: 1.20 x107, rALFA: 7.55 x106), on Calu-3 cells titres reached at 72 hpi (mean PFU/ml rWT: 8.89 x107, rΔMac1: 9.33 x105, rALFA: 2.28 x107) were comparable for rWT and rALFA yet significantly lower for rΔMac1. Immunofluorescence staining confirmed robust expression and cytoplasmic localization of the tagged nsp3. ALFA-tagging allowed for specific, super resolved IF images of Mac1 by anti-ALFA nanobodies in rALFA infected A549 cells. In conclusion, the tagged SARS-CoV-2 represents a versatile tool for functional studies of nsp3 interactions and dynamics of subcellular trafficking during infection, prospectively enabling validation of new therapeutic approaches.
- Open Access
- 22 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1294357
2′-deoxy-ADPR activates human TRPM2 faster than ADPR and thereby induces higher currents at physiological Ca2+ concentrations
TRPM2 is a Ca2+ permeable, non-selective cation channel in the plasma membrane that is involved in the innate immune response regulating, for example, chemotaxis in neutrophils and cytokine secretion in monocytes and macrophages. The intracellular adenine nucleotides ADP-ribose (ADPR) and 2′-deoxy-ADPR (2dADPR) activate the channel, in combination with their co-agonist Ca2+. Interestingly, activation of human TRPM2 (hsTRPM2) by 2dADPR is much more effective than activation by ADPR. However, the underlying mechanism of the nucleotides’ differential effect on the channel is not yet fully understood. In this study, we performed whole-cell patch clamp experiments with HEK293 cells heterologously expressing hsTRPM2. We show that 2dADPR has an approx. 4-fold higher Ca2+ sensitivity than ADPR (EC50 = 190 and 690 nM). This allows 2dADPR to activate the channel at lower and thus physiological intracellular Ca2+ concentrations. Kinetic analysis of our data reveals that activation by 2dADPR is faster than activation by ADPR. Mutation in a calmodulin binding N-terminal IQ-like motif in hsTRPM2 completely abrogated channel activation by both agonists. However, mutation of a single amino acid residue (W1355A) in the C-terminus of hsTRPM2, at a site of extensive inter-domain interaction, resulted in slower activation by 2dADPR and neutralized the difference in rate of activation between the two agonists. Taken together, we propose a mechanism by which 2dADPR induces higher hsTRPM2 currents than ADPR by means of faster channel activation. The finding that 2dADPR has a higher Ca2+ sensitivity than ADPR may indicate that 2dADPR rather than ADPR activates hsTRPM2 in physiological contexts such as the innate immune response.
- 22 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1294357
Open Access2′-deoxy-ADPR activates human TRPM2 faster than ADPR and thereby induces higher currents at physiological Ca2+ concentrations
TRPM2 is a Ca2+ permeable, non-selective cation channel in the plasma membrane that is involved in the innate immune response regulating, for example, chemotaxis in neutrophils and cytokine secretion in monocytes and macrophages. The intracellular adenine nucleotides ADP-ribose (ADPR) and 2′-deoxy-ADPR (2dADPR) activate the channel, in combination with their co-agonist Ca2+. Interestingly, activation of human TRPM2 (hsTRPM2) by 2dADPR is much more effective than activation by ADPR. However, the underlying mechanism of the nucleotides’ differential effect on the channel is not yet fully understood. In this study, we performed whole-cell patch clamp experiments with HEK293 cells heterologously expressing hsTRPM2. We show that 2dADPR has an approx. 4-fold higher Ca2+ sensitivity than ADPR (EC50 = 190 and 690 nM). This allows 2dADPR to activate the channel at lower and thus physiological intracellular Ca2+ concentrations. Kinetic analysis of our data reveals that activation by 2dADPR is faster than activation by ADPR. Mutation in a calmodulin binding N-terminal IQ-like motif in hsTRPM2 completely abrogated channel activation by both agonists. However, mutation of a single amino acid residue (W1355A) in the C-terminus of hsTRPM2, at a site of extensive inter-domain interaction, resulted in slower activation by 2dADPR and neutralized the difference in rate of activation between the two agonists. Taken together, we propose a mechanism by which 2dADPR induces higher hsTRPM2 currents than ADPR by means of faster channel activation. The finding that 2dADPR has a higher Ca2+ sensitivity than ADPR may indicate that 2dADPR rather than ADPR activates hsTRPM2 in physiological contexts such as the innate immune response.
- Open Access
- 15 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 3163
cADPR Does Not Activate TRPM2
CADPR is a second messenger that releases Ca2+ from intracellular stores via the ryanodine receptor. Over more than 15 years, it has been controversially discussed whether cADPR also contributes to the activation of the nucleotide-gated cation channel TRPM2. While some groups have observed activation of TRPM2 by cADPR alone or in synergy with ADPR, sometimes only at 37 °C, others have argued that this is due to the contamination of cADPR by ADPR. The identification of a novel nucleotide-binding site in the N-terminus of TRPM2 that binds ADPR in a horseshoe-like conformation resembling cADPR as well as the cADPR antagonist 8-Br-cADPR, and another report that demonstrates activation of TRPM2 by binding of cADPR to the NUDT9H domain raised the question again and led us to revisit the topic. Here we show that (i) the N-terminal MHR1/2 domain and the C-terminal NUDT9H domain are required for activation of human TRPM2 by ADPR and 2′-deoxy-ADPR (2dADPR), (ii) that pure cADPR does not activate TRPM2 under a variety of conditions that have previously been shown to result in channel activation, (iii) the cADPR antagonist 8-Br-cADPR also inhibits activation of TRPM2 by ADPR, and (iv) cADPR does not bind to the MHR1/2 domain of TRPM2 while ADPR does.
- 15 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 3163
Open AccesscADPR Does Not Activate TRPM2
CADPR is a second messenger that releases Ca2+ from intracellular stores via the ryanodine receptor. Over more than 15 years, it has been controversially discussed whether cADPR also contributes to the activation of the nucleotide-gated cation channel TRPM2. While some groups have observed activation of TRPM2 by cADPR alone or in synergy with ADPR, sometimes only at 37 °C, others have argued that this is due to the contamination of cADPR by ADPR. The identification of a novel nucleotide-binding site in the N-terminus of TRPM2 that binds ADPR in a horseshoe-like conformation resembling cADPR as well as the cADPR antagonist 8-Br-cADPR, and another report that demonstrates activation of TRPM2 by binding of cADPR to the NUDT9H domain raised the question again and led us to revisit the topic. Here we show that (i) the N-terminal MHR1/2 domain and the C-terminal NUDT9H domain are required for activation of human TRPM2 by ADPR and 2′-deoxy-ADPR (2dADPR), (ii) that pure cADPR does not activate TRPM2 under a variety of conditions that have previously been shown to result in channel activation, (iii) the cADPR antagonist 8-Br-cADPR also inhibits activation of TRPM2 by ADPR, and (iv) cADPR does not bind to the MHR1/2 domain of TRPM2 while ADPR does.
- 23 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 14 (675)
HN1L/JPT2: A signaling protein that connects NAADP generation to Ca 2+ microdomain formation
NAADP-evoked Ca2+ release through type 1 ryanodine receptors (RYR1) is a major mechanism underlying the earliest signals in T cell activation, which are the formation of Ca2+ microdomains. In our characterization of the molecular machinery underlying NAADP action, we identified an NAADP-binding protein, called hematological and neurological expressed 1–like protein (HN1L) [also known as Jupiter microtubule-associated homolog 2 (JPT2)]. Gene deletion of Hn1l/Jpt2 in human Jurkat and primary rat T cells resulted in decreased numbers of initial Ca2+ microdomains and delayed the onset and decreased the amplitude of global Ca2+ signaling. Photoaffinity labeling demonstrated direct binding of NAADP to recombinant HN1L/JPT2. T cell receptor/CD3–dependent coprecipitation of HN1L/JPT2 with RYRs and colocalization of these proteins suggest that HN1L/JPT2 connects NAADP formation with the activation of RYR channels within the first seconds of T cell activation. Thus, HN1L/JPT2 enables NAADP to activate Ca2+ release from the endoplasmic reticulum through RYR.
- 23 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 14 (675)
HN1L/JPT2: A signaling protein that connects NAADP generation to Ca 2+ microdomain formation
NAADP-evoked Ca2+ release through type 1 ryanodine receptors (RYR1) is a major mechanism underlying the earliest signals in T cell activation, which are the formation of Ca2+ microdomains. In our characterization of the molecular machinery underlying NAADP action, we identified an NAADP-binding protein, called hematological and neurological expressed 1–like protein (HN1L) [also known as Jupiter microtubule-associated homolog 2 (JPT2)]. Gene deletion of Hn1l/Jpt2 in human Jurkat and primary rat T cells resulted in decreased numbers of initial Ca2+ microdomains and delayed the onset and decreased the amplitude of global Ca2+ signaling. Photoaffinity labeling demonstrated direct binding of NAADP to recombinant HN1L/JPT2. T cell receptor/CD3–dependent coprecipitation of HN1L/JPT2 with RYRs and colocalization of these proteins suggest that HN1L/JPT2 connects NAADP formation with the activation of RYR channels within the first seconds of T cell activation. Thus, HN1L/JPT2 enables NAADP to activate Ca2+ release from the endoplasmic reticulum through RYR.
- Open Access
Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
The nucleotides ATP and NAD+ are released from stressed cells as endogenous danger signals. Ecto-enzymes in the tumor microenvironment hydrolyze these inflammatory nucleotides to immunosuppressive adenosine, thereby, hampering anti-tumor immune responses. The NAD+ hydrolase CD38 is expressed at high levels on the cell surface of multiple myeloma (MM) cells. Daratumumab, a CD38-specific monoclonal antibody promotes cytotoxicity against MM cells. With long CDR3 loops, nanobodies and nanobody-based heavy chain antibodies (hcAbs) might bind to cavities on CD38 and thereby inhibit its enzyme activity more potently than conventional antibodies. The goal of our study was to establish assays for monitoring the enzymatic activities of CD38 on the cell surface of tumor cells and to assess the effects of CD38-specific antibodies on these activities. We monitored the enzymatic activity of CD38-expressing MM and other tumor cell lines, using fluorometric and HPLC assays. Our results showed that daratumumab and hcAb MU1067 inhibit the ADPR cyclase but not the NAD+ hydrolase activity of CD38-expressing MM cells. We conclude that neither clinically approved daratumumab nor recently developed nanobody-derived hcAbs provide a second mode of action against MM cells. Thus, there remains a quest for “double action” CD38-inhibitory antibodies.
Open AccessDaratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
The nucleotides ATP and NAD+ are released from stressed cells as endogenous danger signals. Ecto-enzymes in the tumor microenvironment hydrolyze these inflammatory nucleotides to immunosuppressive adenosine, thereby, hampering anti-tumor immune responses. The NAD+ hydrolase CD38 is expressed at high levels on the cell surface of multiple myeloma (MM) cells. Daratumumab, a CD38-specific monoclonal antibody promotes cytotoxicity against MM cells. With long CDR3 loops, nanobodies and nanobody-based heavy chain antibodies (hcAbs) might bind to cavities on CD38 and thereby inhibit its enzyme activity more potently than conventional antibodies. The goal of our study was to establish assays for monitoring the enzymatic activities of CD38 on the cell surface of tumor cells and to assess the effects of CD38-specific antibodies on these activities. We monitored the enzymatic activity of CD38-expressing MM and other tumor cell lines, using fluorometric and HPLC assays. Our results showed that daratumumab and hcAb MU1067 inhibit the ADPR cyclase but not the NAD+ hydrolase activity of CD38-expressing MM cells. We conclude that neither clinically approved daratumumab nor recently developed nanobody-derived hcAbs provide a second mode of action against MM cells. Thus, there remains a quest for “double action” CD38-inhibitory antibodies.